MAGEA1
Melanoma-associated antigen 1
Also known as: CT1.1, MAGA1_HUMAN, MAGE1, MGC9326
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P43355
- Gene
- MAGEA1
- Ensembl
- ENSG00000198681
- Chromosome
- X
- Canonical length
- 309 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
309 residues, UniProt reviewed canonical sequence.
>P43355|MAGEA1
1 MSLEQRSLHC KPEEALEAQQ EALGLVCVQA ATSSSSPLVL GTLEEVPTAG STDPPQSPQG
61 ASAFPTTINF TRQRQPSEGS SSREEEGPST SCILESLFRA VITKKVADLV GFLLLKYRAR
121 EPVTKAEMLE SVIKNYKHCF PEIFGKASES LQLVFGIDVK EADPTGHSYV LVTCLGLSYD
181 GLLGDNQIMP KTGFLIIVLV MIAMEGGHAP EEEIWEELSV MEVYDGREHS AYGEPRKLLT
241 QDLVQEKYLE YRQVPDSDPA RYEFLWGPRA LAETSYVKVL EYVIKVSARV RFFFPSLREA
301 ALREEEEGVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MAGEA1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 4.4 nTPM
Expression across tissuesHPA
Tissue
- testis: 4.4 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
- appendix: 0 nTPM
- basal ganglia: 0 nTPM
Single-cell type
- early primary spermatocytes: 43 nCPM
- differentiating spermatogonia: 29 nCPM
- undifferentiated spermatogonia: 17 nCPM
- early spermatids: 0.9 nCPM
- late spermatids: 0.6 nCPM
- late primary spermatocytes: 0.2 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MAGEA1.
Disease | ImmuneIEDB
Conditions an epitope on MAGEA1 was assayed in.
- hepatocellular carcinoma T cell
- melanoma T cell
- skin melanoma T cell
- anaplastic oligodendroglioma T cell
- testicular germ cell cancer T cell
- lung non-small cell carcinoma T cell
- ovarian serous carcinoma T cell
- liver cirrhosis T cell
- hepatitis B T cell
- hepatitis C T cell
- cancer T cell
- colorectal cancer T cell
- pancreatic adenocarcinoma T cell
- brain glioblastoma multiforme T cell
- anaplastic astrocytoma T cell
ReferencesPubMed · IEDB
Publications for MAGEA1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Diagnostic performance of anti-MAGEA family protein autoantibodies in esophageal squamous cell carcinoma.
2023 · Int Immunopharmacol · RCR 0.5 · 4 citations - [Evaluation of the application value of seven tumor-associated autoantibodies in non-small cell lung cancer based on machine learning algorithms].
2023 · Zhonghua Yu Fang Yi Xue Za Zhi · RCR 0.1 · 1 citations - Clinical application of serum seven tumour-associated autoantibodies in patients with pulmonary nodules.
2024 · Heliyon · RCR 0.1 · 1 citations
Reference: B cellIEDB
3 publications
- Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response.
2019 · Int J Nanomedicine · RCR 1.4 · 29 citations - A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3.
2005 · J Biol Chem · RCR 1.1 · 66 citations - Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.
2016 · Int J Nanomedicine · RCR 1 · 28 citations
Reference: T cellIEDB
32 publications
- A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy.
2025 · Nat Biotechnol · RCR 19.4 · 68 citations - A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
1992 · J Exp Med · RCR 13.5 · 631 citations - SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals.
2021 · J Clin Invest · RCR 9.6 · 209 citations - Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
2014 · Hepatology · RCR 7.8 · 298 citations - Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
2021 · Immunity · RCR 5.3 · 114 citations
Show 20 more of 32 total
- Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
2023 · Nat Commun · RCR 3.9 · 55 citations - VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens.
2024 · Front Immunol · RCR 2.4 · 8 citations - A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
2013 · Clin Cancer Res · RCR 2.3 · 92 citations - Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.
2021 · J Immunother Cancer · RCR 2.2 · 45 citations - Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
2012 · Oncol Rep · RCR 2.2 · 88 citations - Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay.
1997 · Int J Cancer · RCR 2 · 100 citations - A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients.
2023 · Int J Mol Sci · RCR 1.8 · 20 citations - α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
2012 · BMC Cancer · RCR 1.8 · 71 citations - Cross-reactive CD8+ T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs).
2024 · J Exp Clin Cancer Res · RCR 1.4 · 13 citations - Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
2004 · Hum Immunol · RCR 1.2 · 65 citations - Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes.
1997 · J Immunol · RCR 1.1 · 62 citations - In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides.
1995 · Mol Immunol · RCR 1.1 · 49 citations - Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
2024 · Pharmacol Res · RCR 0.8 · 7 citations - Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma.
2019 · Oncotarget · RCR 0.8 · 27 citations - Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
2021 · J Immunother Cancer · RCR 0.7 · 13 citations - A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
2023 · Mol Ther Oncolytics · RCR 0.7 · 14 citations - Spontaneous CD4+ and CD8+ T-cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients.
2017 · Eur J Immunol · RCR 0.7 · 21 citations - Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
2020 · Front Immunol · RCR 0.7 · 19 citations - The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent.
2019 · J Immunol · RCR 0.6 · 19 citations - Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
2020 · Elife · RCR 0.6 · 17 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD missense Z
- 0.98
- DepMap mean gene effect
- 0.18
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of Notch signaling pathway
- negative regulation of transcription by RNA polymerase II
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MAGEA1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MAGEA1 as an antibody target. Whether an autoantibody or antibody against MAGEA1 could matter depends on whether native MAGEA1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MAGEA1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MAGEA1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...